GAO Report on Medicare Part D Finds PBMs Earned Little Revenue From Spread Pricing
August 16th 2019With rising concern over rising drug prices, policymakers have sought a better understanding of the roles of pharmacy benefit managers (PBMs) in the drug supply chain and plans' and PBMs' efforts to manage Part D drug spending and use.
Samsung Bioepis Begins Recruiting Patients for Phase 3 Trial of Eculizumab Biosimilar, SB12
August 16th 2019Samsung Bioepis has begun recruiting patients with paroxysmal nocturnal hemoglobinuria (PNH) in India for a phase 3 clinical study of its proposed eculizumab biosimilar, SB12, referencing Soliris.
Point-of-Care Test Nearly Identical to ELISA at Detecting ADAs to Biosimilar Infliximab, SB2
August 15th 2019A recent study of a rapid point-of-care (POC) test shows that it is virtually identical at detecting antidrug antibodies (ADAs) to a biosimilar infliximab, SB2 (Renflexis, Flixabi), as a standard enzyme-linked immunosorbent assay (ELISA) and is suitable for therapeutic drug monitoring of any infliximab product.
Biosimilar Etanercept, LBEC0101, Is Safe and Effective Up to Week 100 in RA
August 15th 2019LG Chem’s biosimilar etanercept, LBEC0101, referencing Enbrel, recently gained approval in Japan and the Republic of Korea. Among the data that led to its authorization were those deriving from a phase 3 study that demonstrated the biosimilar had equivalent efficacy and a comparable safety profile to the reference product. Recently, researchers reported on a single-arm, open-label extension study in patients with rheumatoid arthritis (RA) who completed the 52-week phase 3 study.
UnitedHealthcare Will Prefer Amgen's Anticancer Biosimilars Beginning in October
August 15th 2019In its August 2019 network bulletin, UnitedHealthcare indicated that, beginning October 1, 2019, biosimilar bevacizumab (Mvasi) and biosimilar trastuzumab (Kanjinti), both made by Amgen, will be preferred products for commercial and community plans.
Exclusivity for Biologic Products Under the USMCA: What Is Changing, and What Happens Next?
August 14th 2019Negotiations between Congress and the Trump administration over ratification and implementation of the United States–Mexico–Canada Agreement (USMCA) have picked up speed in recent weeks. The USMCA was signed on November 30, 2018, ostensibly as a replacement for the original North American Free Trade Agreement (NAFTA).
Eye on Pharma: FDA Gives Green Light to Aflibercept in Prefilled Syringe
August 14th 2019Regeneron’s aflibercept (Eylea) has been approved by the FDA for a prefilled syringe (PFS) presentation. The 2-mg, single-dose, PFS will offer the greater ease of use less preparation than the vial presentation of the drug used to treat a range of eye disorders.
Fresenius Kabi's Biosimilar Adalimumab, Idacio, Is Similar to Humira in RA in Terms of Safety
August 13th 2019This month, researchers published data from a phase 3 study of the biosimilar in patients with moderate to severe rheumatoid arthritis (RA) after previous phase 3 data were reported for a study in patients with severe plaque psoriasis.
Canada Announces Reforms to Reduce Prices on Patented Drugs
August 12th 2019The Canadian government has announced amendments to its regulations concerning patented drugs that it says will make medicines more affordable. According to Health Canada, these changes will save Canadians $13.2 billion (US $9.97 billion) over the next decade.
Patients Say They Are Ready for Cost-Saving Biosimilar Insulin
August 10th 2019Winnie Tiedemann, 73, of New Jersey lives with her son and his 5 children. Tiedemann was diagnosed with diabetes at age 25 and has been insulin-dependent for the past 20 or so years. Her out of pocket costs for insulin? Around $3600 a year.
Key Access-Related Considerations for Anticancer Biosimilar Entrants
August 9th 2019There remain many uncertainties and questions around the success of these agents. It is therefore critical for sponsors and other stakeholders to consider some of the potential hurdles and policy shifts facing anticancer biosimilar uptake and ultimately reimbursement in the United States.
Change Dosing Regimens To Lower Drug Costs? It's Possible, Researchers Say
August 9th 2019The August issue of JAMA Oncology features a Viewpoint that puts forth a free-market solution to lower high drug costs by changing dosing regimens without hurting efficacy using the approach of interventional pharmacoeconomics (IVPE).
Oncology Group Says It Has Begun Treating Patients With Biosimilar Trastuzumab and Bevacizumab
August 8th 2019OneOncology, a national partnership of community oncology practices, says that its partner practices have begun treating patients with 2 anticancer biosimilars: Kanjinti, a trastuzumab biosimilar referencing Herceptin, and Mvasi, a bevacizumab biosimilar referencing Avastin.
UK Group Reports on a Successful Switch to Biosimilar Etanercept
August 7th 2019Anti–tumor necrosis factor medicines are one of the costliest drugs for many health systems, and in the United Kingdom, a recent article described how one clinical commissioning group managed the switch of patients on the originator etanercept (Enbrel) to a biosimilar (Benepali) using a fixed-price model.
IGBA's Trade Principles Address Regulatory Convergence and Intellectual Property Concerns
August 7th 2019The International Generic and Biosimilars Medicines Association (IGBA), which represents generic and biosimilar medicines associations worldwide, recently released its report on how trade agreements can foster generic and biosimilar medicines and improve patient access to care.
Paper Proposes Methodology to "Protect Health Systems" That Use Biosimilars
August 7th 2019A study published this month proposes that biosimilars be assessed in a quantitative benefit-risk analysis to assess whether what the authors call “uncertainty in the clinical performance of biosimilars” can be countered by lower pricing.